Shift of antibiotic resistance after the COVID-19 pandemic: results from the INVIFAR Network.

Publication date: Aug 01, 2026

In this study, we evaluated temporal changes in antimicrobial resistance (AMR) before, during and after the COVID-19 pandemic in Mexico. We conducted a multicentre, retrospective surveillance study that included clinically significant isolates of Gram-positive and Gram-negative bacteria collected across Mexico between January 2019 and December 2024. Differences in antibiotic resistance among clinical specimen types and across pre-pandemic, pandemic and post-pandemic periods were assessed using Fisher’s exact test and linear regression, as appropriate. A total of 156 193 isolates were analysed. Among Enterobacterales, extended-spectrum β-lactamase-producing Escherichia coli increased from the pre-pandemic to post-pandemic period (46. 5%-48. 9%, P for trend = 0. 005). Also, resistance to ertapenem (2. 0% to 3. 2%) and meropenem (1. 2% to 2. 7%) increased significantly (both P for trend 

Concepts Keywords
Antibiotic
Covid
Evaluated
Gram
Increased
Invifar
Isolates
Mexico
Network
Pandemic
Post
Pre
Resistance
Shift
Study

Semantics

Type Source Name
disease MESH COVID-19 pandemic
disease MESH included
drug DRUGBANK Ertapenem
drug DRUGBANK Meropenem

Original Article

(Visited 3 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *